Citations

Clear

387 citation(s) found for "Couch, Fergus".

Abstract 7130: Spatially resolved single-cell analysis reveals cGAS-STING-mediated tumor-immune interactions via IFNα as determinants of pembrolizumab sensitivity in triple-negative breast cancer
Liu, Yi , Chumsri, Saranya , Ma, Yaohua , Perez, Edith A. , Leon‐Ferre, Roberto A. , Zahrieh, David M. , Knutson, Keith L. , Thompson, E. Aubrey , Carter, Jodi M. , Nassar, Aziza , Hillman, David W. , Boughey, Judy C. , Ingle, James N. , Kalari, Krishna R. , Couch, Fergus J. , Goetz, Matthew P. , Knutson, Keith L.

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 7130-7130

10.1158/1538-7445.am2025-7130 Get It

Abstract Purpose: While an addition of immune checkpoint inhibitor (ICI), pembrolizumab, has improved outcomes of patients with TNBC, early-stage TNBC patients with residual cancer burden (RCB) II/III after neoadjuvant chemotherapy in combination with pembrolizumab (NAP) still have poor outcomes. Previously, we demonstrated that intratumoral HLA-DRA expression and interferon-alpha (IFNα) responses were associated with immune-inflamed phenotype and better outcomes in TNBC patients receiving chemotherapy. This study utilized the CosMx™ SMI to investigate in early-stage TNBC treated with NAP. Methods: Of 151 samples from TNBC patients treated with NAP at Mayo Clinic, 8 pre-treatment biopsy samples (5 pCR and 3 RCB II/III were analyzed using the CosMx™ SMI platform. Linear mixed models to assess differential expression (DE), adjusting for hierarchical data structures. DE analyses were expressed as log2-fold changes (logFC), with the Benjamini-Yekutieli method. GSEA and IPA for signaling pathway exploration. Results: 1.7 million cells were identified across 8 samples after stringent quality control. Immune cell profiling revealed higher B cells, plasma cells, plasmablasts, and T cells (CD4 and CD8) in responders, whereas fibroblasts and myeloid cells were enriched in non-responders. DE analysis showed significantly elevated expression of HLA-DRA (logFC 1.955, p<0.001), other MHC class I and II components, and IFNα in responders. Tumor cells in responders exhibited the highest IFNα expression across cell types. GSEA and IPA analysis revealed enrichment in interferon signaling, antigen presentation, and the cGAS-STING pathway, which drives IFNα production. Spatial analysis categorized cells by their proximity to tumor cells: within 50 µm, 50-100 µm, and over 100 µm. T cells, particularly CD8 T cells, showed a distance-dependent distribution, with a higher abundance near tumor cells in responders. CD8 T cell activation scores declined with increasing distance from IFNα-positive tumor cells but remained consistently low near IFNα-negative tumor cells. IFNγ-positive CD8 T cells exhibited higher activation compared to IFNγ-negative cells, with activation levels influenced by proximity to tumor cells. Lastly, MHC expression in tumor cells was examined relative to CD8 T cell proximity. HLA-DRA and CIITA expression decreased as tumor cells were farther from CD8 T cells. Conclusions: This spatially resolved single-cell analysis highlights the pivotal role of tumor-immune interactions in response to pembrolizumab in TNBC. Our data suggest that tumor cells secrete IFNα through the activation of the cGAS-STING pathway, which activates T cells within close proximity, highlighting the potential role of cGAS-STING agonist as well as IFNα signaling and antigen presentation in augmenting TNBC responses to ICIs. Citation Format: Yi Liu, Saranya Chumsri, Yaohua Ma, Jodi M. Carter, Aziza Nassar, Edith Perez, Roberto A. Leon-Ferre, David Zahrieh, David W. Hillman, Judy C. Boughey, James Ingle, Krishna R. Kalari, Fergus J. Couch, Matthew P. Goetz, Keith L. Knutson, E. Aubrey Thompson. Spatially resolved single-cell analysis reveals cGAS-STING-mediated tumor-immune interactions via IFNα as determinants of pembrolizumab sensitivity in triple-negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7130.
Abstract 7118: Clinical characteristics and survival outcomes of ovarian cancer among South Asian women in United States
Karki, Aditi, Yadav, Sumeet Kumar, Islam, Muhammad Rafiqul, Dangol, Ramila Shilpakar, Aziz, Zeba , Pruthi, Sandhya , Shahi, Maryam , Couch, Fergus J., Karki, Aditi, Pramanik, Raja , Bakkum‐Gamez, Jamie N. , Kaufmann, Scott H. , Yadav, Siddhartha

Mayo Clinic

Cancer Research | April 21, 2025 | Volume: 85 | Issue: 8_Supplement_1 | Pages: 7118-7118

10.1158/1538-7445.am2025-7118 Get It

Abstract Background: Ovarian cancer is the sixth leading cause of cancer deaths among women in the United States. South Asians in the USA, including Asian Indians and Pakistani Americans (AIPA), are a rapidly growing yet under-researched group. This study aims to analyze the clinical features, survival rates, treatment, and outcomes of ovarian cancer among AIPA women in the United States. Methods: Adult women diagnosed with ovarian cancer between 2000 and 2023 within the Surveillance, Epidemiology, and End Results (SEER) registry were identified utilizing ICD codes. The analysis focused on comparing clinical characteristics and outcomes between AIPA and Non-Hispanic White (NHW)women and excluded all women of other races/ethnicities or unknown race/ethnicity. Baseline characteristics, including age at diagnosis, disease stage, and treatment, were compared between AIPA and NHW women utilizing a chi-squared test for categorical variables and a t-test for continuous variables. The 5-year overall survival (OS) was estimated for each race/ethnicity by the Kaplan-Meier method, and the OS was further compared between AIPA and NHW in a cox-proportional hazard regression analysis adjusting for age at diagnosis, grade, histology, TNM stage, surgical debulking, completeness of debulking surgery, and receipt of chemotherapy. Similar comparisons of baseline characteristics and OS were also performed in the subset of women with high-grade serous ovarian cancer (HGSOC). Result: A total of 86, 485 women met the inclusion criteria, of which 1, 179 were AIPA and 85, 306 were NHW. AIPA had a significantly younger median age at diagnosis compared to NHW women in the overall population (57 vs. 65 years, p<0.001) and among 448 AIPA and 29, 677 NHW women with HGSOC (58 vs. 65 years, p<0.001). Approximately two-thirds of women in both groups presented with Stage III or IV ovarian cancer at diagnosis and had a serous subtype of ovarian cancer. Similarly, after the exclusion of unknown grade, high-grade tumors accounted for more than two-thirds (75 vs. 72%) of the ovarian cancer cases in both groups. AIPA were more likely to undergo debulking surgery (85 vs. 80%, p<0.001) and receive chemotherapy (77 vs. 72%, p<0.001) compared to NHW women. The unadjusted 5-year OS for AIPA and NHW women were 56% vs. 43% in the overall population, and 53% vs. 41% among women with HGSOC, respectively. In multivariate analysis of the entire study population, AIPA women had a significantly better OS than NHW women (HR: 0.86, 95%CI: 0.79 - 0.94, p<0.001). Among women with HGSOC, a similar trend of better OS was noted in multivariate analysis among AIPA women compared to NHW (HR: 0.88, 95%CI: 0.77 - 1.01, p=0.07), although this did not reach statistical significance. Conclusion: The younger age at diagnosis, along with a generally better prognosis, among AIPA women compared to NHW women, suggests a possible enrichment of DNA-repair gene alterations among AIPA women. Citation Format: Aditi Karki, Sumeet Kumar Yadav, Muhammad Rafiqul Islam, Raja Pramanik, Ramila Shilpakar Dangol, Zeba Aziz, Sandhya Pruthi, Maryam Shahi, Jamie N. Bakkum-Gamez, Scott H. Kaufmann, Fergus J. Couch, Siddhartha Yadav. Clinical characteristics and survival outcomes of ovarian cancer among South Asian women in United States [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 1 (Regular Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_1):Abstract nr 7118.
Trajectory of Global Mental Health and Global Physical Health in Breast Cancer Survivorship
Pritzl, Stephanie L., Ruddy, Kathryn J. , Larson, Nicole L. , Ehlers, Shawna L. , Vierkant, Robert A. , Stan, Daniela , Olson, Janet E. , Couch, Fergus J. , Higgins, Alexandra

Mayo Clinic

Journal of the National Comprehensive Cancer Network | April 14, 2025 | Volume: 23 | Issue: 5 | Pages: 141-146

10.6004/jnccn.2024.7353 | PMID 40228538 Get It

Background: Breast cancer survivors face a risk of significant psychological distress, which can persist for years after their initial diagnosis. Although numerous guidelines and tools exist to help screen for and measure distress in patients with cancer, additional longitudinal studies are needed to better characterize the trajectory of distress over time. Patients and Methods: We conducted a longitudinal study to evaluate distress and health-related quality of life in patients with breast cancer. Annual assessments included global mental and physical health scores using the Patient-Reported Outcomes Measurement Information System Global-10 (PROMIS-10), posttraumatic stress symptoms using the Impact of Event Scale-Revised (IES-R), and depressive symptoms using the Patient Health Questionnaire-2 (PHQ-2). Eligible participants had stage 0–III breast cancer, with baseline surveys administered within 1 year of diagnosis. Annual follow-up surveys were conducted through year 4 after the baseline survey. Only patients who completed the baseline survey and at least one follow-up survey were included in this analysis. Individuals with stage IV or recurrent breast cancer were excluded. Results: A total of 2,140 individuals were included. Over time, global mental health scores declined slightly, with differences in T-scores from baseline ranging from 0.4 to 0.9. In contrast, global physical health scores improved, with differences in T-scores ranging from 0.3 to 0.6. Mean scores remained in the normative range. Depressive symptoms remained stable throughout the study period, while posttraumatic stress symptoms showed improvement over time. Conclusions: This study provides important longitudinal data on distress subtypes in breast cancer survivors with nonmetastatic disease. Although global mental health declined slightly, depression symptoms remained stable, and posttraumatic stress symptoms improved. Investigation of distress subtypes over time merits further study to advance detection of significant distress across the cancer continuum.
p16, COX-2, and Ki67 Protein Expression in DCIS and Risk of Ipsilateral Invasive Breast Cancer
Rohan, Thomas E. , Zhang, Chenxin , Wang, Yihong , Couch, Fergus J. , Greenlee, Robert T. , Honda, Stacey , Stark, Azadeh , White, Larissa L. , Chitale, Dhananjay , Xue, Xiaonan , Ginsberg, Mindy , Loudig, Olivier , Wang, Yihong , Couch, Fergus J. , Chitale, Dhananjay A , Loudig, Olivier

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | April 14, 2025 | Volume: 34 | Issue: 6 | Pages: 1036-1039

10.1158/1055-9965.epi-25-0143 | PMID 40227115 Get It

Abstract Background: Prior research on the associations of p16, COX-2, and Ki67 immunopositivity in ductal carcinoma in situ (DCIS) tissue with the risk of subsequent ipsilateral invasive breast cancer (IBC) is limited. Methods: In a case–control study nested in a cohort of women diagnosed with DCIS, immunostaining for p16, COX-2, and Ki67 was performed on DCIS tissue from those who developed subsequent ipsilateral IBC (cases; n = 146) and on matched subjects who did not develop IBC (controls; n = 273). Conditional logistic regression was used to estimate ORs and 95% confidence intervals for the associations between immunopositivity for p16, COX-2, and Ki67 and the risk of subsequent ipsilateral IBC. Results: There was no association between p16, COX-2, and Ki67 immunopositivity, examined either individually or in combination, and a risk of ipsilateral IBC. Compared with all other groups, the multivariable OR (95% confidence interval) for women who were triple positive for the three markers was 1.16 (0.38–3.54). Conclusions: p16, COX-2, and Ki67 immunopositivity was not associated with altered risk of ipsilateral IBC in women with DCIS. Impact: p16, COX-2, and Ki67 may not be prognostic for ipsilateral IBC in women with DCIS.
Interactions between genetic and epidemiological factors influencing mammographic density
Suger, Austin Hammermeister , Chen, Hongjie , Fan, Shaoqi , Bolla, Manjeet K. , Michailidou, Kyriaki , Wang, Qin , Fasching, Peter A. , Haeberle, Lothar, Aronson, Kristan J. , Eccles, Diana M, Evans, D. Gareth , Astley, Susan , Hall, Per, Pharoah, Paul D P, Antoniou, Antonis C, García‐Closas, Montserrat , González, Amy Berrington de , Easton, Douglas F. , Vachon, Celine M. , Lindström, Sara, Eccles, Diana , Fan, Shaoqi , Bolla, Manjeet K , Dennis, Joe , Michailidou, Kyriaki , Wang, Qin , Stone, Jennifer , Yadav, Siddhartha , Milne, Roger L , Norman, Aaron, Hall, Per N , Czene, Kamila , Pharoah, Paul D P , García-Closas, Montserrat , Easton, Doug , Eccles, Diana , Evans, D Gareth , Berrington de Gonzalez, Amy , Haas, Cameron B. , Scott, Christopher G. , Dunning, Alison M. , Stone, Jennifer , Gago-Domínguez, Manuela , Castelao, Jose E. , Murphy, Rachel A. , Couch, Fergus J. , Yadav, Siddhartha , Milne, Roger L. , Hopper, John L. , Norman, Aaron D. , Eliassen, A. Heather , Tapper, William , Czene, Kamila , Antoniou, Antonis C. , Gierach, Gretchen L. , Tamimi, Rulla M. , Vachon, Celine M. , Harrison, Tabitha A.

Mayo Clinic

American Journal of Epidemiology | March 30, 2025 | Volume: 195 | Issue: 5 | Pages: 1231-1241

10.1093/aje/kwaf067 | PMID 40153356 Get It

Abstract Studies have identified genetic and epidemiologic factors associated with mammographic density (MD) phenotypes. However, MD-associated genetic variants only account for a small proportion of the total estimated heritability. Interrogating interactions between genetic and epidemiologic factors could potentially identify additional MD-associated loci, expand our understanding of the genetic basis of MD phenotypes, and clarify how epidemiologic factors modulate relationships between genetic variants and MD. We conducted six separate genome-wide, gene–environment (GxE) interaction analyses, applying 2 degrees of freedom (df) and 1df interaction tests, for each of three MD phenotypes (percent density, dense area (DA), and nondense area (NDA)). The six epidemiologic factors considered were height, ever parous, parity, ever menopausal hormone therapy, ever breastfeeding, and months of breastfeeding. We included European ancestry participants from multiple studies within the Markers of Density consortium and the Breast Cancer Association Consortium (n = 4895-16 218 depending on specific analyses). We identified 11 loci with genome-wide significant (P < 5 × 10−8) interaction tests including two novel common genetic signals interacting with parity (8p21.2) and ever breastfeeding (19p13.2) for NDA. Our results suggest that epidemiologic risk factors might influence relationships between common genetic variants and MD phenotypes at particular genomic loci.
Germline–Somatic Interactions in BRCA-Associated Cancers: Unique Molecular Profiles and Clinical Outcomes Linking ATM to TP53 Synthetic Essentiality
Arafa, Ali T., Yadav, Siddhartha , Marshall, Catherine H. , Mauer, Elizabeth , Huang, Minxuan , Yilma, Binyam , Pol, Ymke van der , Fragkogianni, Stamatina , Teslow, Emily A. , Kellen, Samuel , Boytim, Ella , Luo, Christine , Ludwig, Megan , Jayaraj, Arockia, Armstrong, Deborah K. , Isaacs, William B. , Nguyen, Hai Dang , Huang, R. Stephanie , Dehm, Scott M. , Hwang, Justin H. , Arafa, Ali T. , Arafa, Ali , van der Pol, Ymke , Zhang, Weijie , Jayaraj, Arockia , Armstrong, Deborah K , Isaacs, William B , Drake, Justin M , Nguyen, Hai Dang , Huang, R Stephanie , Chao, Calvin Y. , Lou, Emil , Dehm, Scott M , Couch, Fergus J. , Hwang, Justin H , Antonarakis, Emmanuel S , Mauer, Elizabeth , Yadav, Siddhartha , Marshall, Catherine H , Teslow, Emily A , Fragkogianni, Stamatina , Lou, Emil , Couch, Fergus J. , Antonarakis, Emmanuel S.

Mayo Clinic

Clinical Cancer Research | February 28, 2025 | Volume: 31 | Issue: 9 | Pages: 1730-1745

10.1158/1078-0432.ccr-24-2058 | PMID 40019487 Get It

Abstract Purpose: Germline alterations in homologous recombination repair (gHRR) genes affect the pathogenesis, treatment options, and survival of patients with cancer. However, distinct gHRR gene alterations may differentially affect treatment response and oncogenic signaling. In this study, we interrogated genomic and transcriptomic data and assessed clinical outcomes of patients with gHRR mutations across four BRCA-associated cancers (breast, ovarian, pancreatic, and prostate cancers) to identify therapeutic vulnerabilities. Experimental Design: We assessed 24,309 patients undergoing matched tumor/normal next-generation DNA and RNA sequencing. Annotated gHRR gene variants [germline BRCA1, germline BRCA2, germline PALB2, germline ATM (gATM), and germline CHEK2] were analyzed. HRs were used to assess survival outcomes comparing germline versus sporadic groups. Somatic alterations and their frequencies were compared across gHRR-altered groups. Differential gene expression and gene set enrichment analysis were used to compare transcriptomic profiles. Results: Somatic TP53 mutations were depleted in gATM carriers (P < 0.05) across all four BRCA-associated cancers by up to 2.5-fold. Tumors with germline BRCA1/2 mutations were associated with improved survival in patients with ovarian cancer and had consistent enrichment of TP53 mutations in all four cancers. gATM mutations displayed elevated p53 transcriptional activity in all four cancers, with significance reached in breast and prostate cancers (P < 0.01). In breast, ovarian, and prostate cancers, gATM tumors demonstrated significantly increased inflammatory pathways (P < 0.001). Finally, using gene dependency data, we found that cell lines that were highly dependent on ATM were co-dependent on canonical p53 function. Conclusions: gATM-associated cancers seem to require intact p53 activity and this synthetic essentiality may be used to guide targeted therapies that perturb canonical TP53 function.
Musician's Experience After Breast Cancer Treatment: Defining Musical Toxicity and its Frequency
Burlile, Jessica F. , Cameron, Joshua, Larson, Nicole L. , Bradt, Jennifer L., Boughey, Judy C. , Mrdutt, Mary M., Couch, Fergus J. , Olson, Janet E. , Cangie, Valerie, Ehlers, Shawna L. , Sharifzadeh, Yasamin , Ruddy, Kathryn J. , Shumway, Dean A. , Loprinzi, Charles L. , Boughey, JC , Couch, Fergus J. , Cameron, Joshua D , Gunn, Heather , Larson, Nicole , Olson, Janet E , Ehlers, Shawna , Sharifzadeh, Yasamin , Ruddy, Kathryn J , Loprinzi, Charles , Cathcart-Rake, Elizabeth J , Burlile, Jessica , Mrdutt, Mary M , Gunn, Heather , Cathcart-Rake, Elizabeth

Mayo Clinic

JCO Oncology Practice | January 22, 2025 | Volume: 21 | Issue: 8 | Pages: 1142-1152

10.1200/op-24-00729 | PMID 39841944 Get It

PURPOSE Over 50% of households in the United States have at least one musician—many musicians are also breast cancer survivors. This group has not been well studied, and given the level of fine sensory-motor skill required for musicianship, we hypothesized that musicians experience unique manifestations of breast cancer treatment toxicities. METHODS A nine-item Musical Toxicity Questionnaire (MTQ) was distributed to patients who had consented to participate in the Mayo Clinic Breast Cancer Registry. The MTQ screened participants by asking if they played a musical instrument or sang in the last 10 years: questions populated for those who answered yes. Respondents were asked if they noticed difficulty with their musical endeavor during or after breast cancer treatment, defined as acute musical toxicity (AMT). The questionnaire asked which side effect and cancer-directed therapy most influenced musical ability, what musical attributes were affected, and the timeline of resolution. Multivariable and classification tree analyses assessed relationships between AMT and treatment characteristics. RESULTS Of 1,871 survey respondents, 29% (535/1,871) self-identified as musicians. Over a quarter (27%, 144/535) reported AMT, and for 57% (82/144), AMT had not resolved at the time of survey. Of the treatments each participant received, chemotherapy was most often reported as most negatively impactful (63/89 who received chemotherapy, 71%). Decreased endurance was the most common musical difficulty (64% of those with AMT, 92/144), followed by decreased accuracy, trouble playing/singing quickly, and difficulty using proper technique. Multivariable and classification tree analyses revealed that receipt of chemotherapy was most strongly correlated with AMT. CONCLUSION These results will help oncology care teams counsel musicians, answer questions about impacts on musicality, and provide a timeline for resolution of musical symptoms.
Pathogenic Variants in Cancer Susceptibility Genes Predispose to Ductal Carcinoma In Situ of the Breast
Huang, Huaizhi , Couch, Ronan E. , Karam, Rachid , Boddicker, Nicholas , Polley, Eric C. , Na, Jie , Ambrosone, Christine B. , Yao, Song , Trentham‐Dietz, Amy , Bodelón, Clara , Hodge, James M. , Patel, Alpa V. , Haiman, Christopher A. , John, Esther M. , Vachon, Celine M. , Ruddy, Kathryn J. , Goldgar, David E. , Nathanson, Katherine L. , Weitzel, Jeffrey N. , Dolinsky, Jill S. , Pesaran, Tina , Hu, Chunling , Boddicker, Nicholas J , Polley, Eric C , Na, Jie , Ambrosone, Christine B , Yao, Song , Trentham-Dietz, Amy , Eliassen, A Heather , Penney, Kathryn , Brantley, Kristen D , Bodelon, Clara , Teras, Lauren R , Hodge, James M , Patel, Alpa V , Haiman, Christopher A , John, Esther M , Neuhausen, Susan L. , Martı́nez, Marı́a Elena , Lacey, James V. , O'Brien, Katie M , Sandler, Dale P , Weinberg, Clarice R , Palmer, Julie R , Bertrand, Kimberly A , Vachon, Celine M. , Olson, Janet E , Ruddy, Kathryn J , Anton-Culver, Hoda , Ziogas, Argyrios , Goldgar, David E , Nathanson, Katherine L , Domchek, Susan M , Weitzel, Jeffrey N , Kraft, Peter , Dolinsky, Jill S , Pesaran, Tina , Richardson, Marcy E , Yadav, Siddhartha , Couch, Fergus J. , Karam, Rachid , Huang, Huaizhi , Couch, Ronan , Hu, Chunling , Eliassen, A. Heather , Brantley, Kristen D. , Teras, Lauren R. , O’Brien, Katie M. , Sandler, Dale P. , Weinberg, Clarice R. , Palmer, Julie R. , Bertrand, Kimberly A. , Olson, Janet E. , Anton‐Culver, Hoda , Ziogas, Argyrios , Domchek, Susan M. , Kraft, Peter , Yadav, Siddhartha , Couch, Fergus J.

Mayo Clinic

Clinical Cancer Research | November 8, 2024 | Volume: 31 | Issue: 1 | Pages: 130-138

10.1158/1078-0432.ccr-24-1884 | PMID 39513960 Get It

Abstract Purpose: To determine the relationship between germline pathogenic variants (PV) in cancer predisposition genes and the risk of ductal carcinoma in situ (DCIS). Experimental Design: Germline PV frequencies in breast cancer predisposition genes (ATM, BARD1, BRCA1, BRCA2, CDH1, CHEK2, PALB2, RAD51C, and RAD51D) were compared between DCIS cases and unaffected controls and between DCIS and invasive ductal breast cancer (IDC) cases from a clinical testing cohort (n = 9,887), a population-based cohort (n = 3,876), and the UK Biobank (n = 2,421). The risk of contralateral breast cancer (CBC) for DCIS cases with PV was estimated in the population-based cohort. Results: Germline PV were observed in 6.5% and 4.6% of women with DCIS in the clinical testing and population-based cohorts, respectively. BRCA1, BRCA2, and PALB2 PV frequencies were significantly lower among women with DCIS than those with IDC (clinical cohort: 2.8% vs. 5.7%; population-based cohort: 1.7% vs. 3.7%), whereas the PV frequencies for ATM and CHEK2 were similar. ATM, BRCA1, BRCA2, CHEK2, and PALB2 PV were significantly associated with an increased risk of DCIS (OR > 2.0), but only BRCA2 PV were associated with high risk (OR > 4) in both cohorts. The cumulative incidence of CBC among carriers of PV in high-penetrance genes with DCIS was 23% over 15 years. Conclusions: The enrichment of PV in ATM, BRCA1, BRCA2, CHEK2, and PALB2 among women with DCIS suggests that multigene panel testing may be appropriate for women with DCIS. Elevated risks of CBC in carriers of PV in high-penetrance genes with DCIS confirmed the utility of testing for surgical decision-making.
Polygenic risk scores stratify breast cancer risk among women with benign breast disease
Sherman, Mark E. , Winham, Stacey J. , Vierkant, Robert A. , McCauley, Bryan M. , Scott, Christopher G. , Schrup, Sarah E. , Gaudet, Mia M. , Troester, Melissa A. , Pruthi, Sandhya , Bolla, Manjeet K. , Wang, Qin , Dennis, Joe, Chang‐Claude, Jenny , Obi, Nadia, Aronson, Kristan J. , García‐Closas, Montserrat , Yang, Xiaohong R. , Pharoah, Paul D.P., Easton, Douglas F., Vachon, Celine M, Schrup, Sarah, Radisky, Derek C. , Wang, Qin , Dennis, Joe , Michailidou, Kyriaki , Truong, Therese , Obi, Nadia , Aronson, Kristan J , García-Closas, Montserrat , Chanock, Stephen Jacob , Yang, Xiaohong R , Mavaddat, Nasim , Easton, Doug , Vachon, Celine M. , Winham, Stacey J , Vierkant, Robert A , Scott, Christopher , Gaudet, Mia M , Sherman, Mark E , Degnim, Amy C. , Couch, Fergus J. , Michailidou, Kyriaki , Guénel, Pascal , Truong, Thérèse , Murphy, Rachel A. , Ahearn, Thomas U. , Dunning, Alison M. , Easton, Douglas F.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | October 16, 2024 | Volume: 117 | Issue: 3 | Pages: 456-464

10.1093/jnci/djae255 | PMID 39412492 Get It

Abstract Background Most breast biopsies are diagnosed as benign breast disease, with 1.5- to 4-fold increased breast cancer risk. Apart from pathologic diagnoses of atypical hyperplasia, few factors aid in breast cancer risk assessment of these patients. We assessed whether a 313–single nucleotide variation (formerly single-nucleotide polymorphism) polygenic risk score stratifies risk of benign breast disease patients. Methods We pooled data from 5 Breast Cancer Association Consortium case-control studies (mean age = 59.9 years), including 6706 participants with breast cancer and 8488 participants without breast cancer. Using logistic regression, we estimated breast cancer risk associations by self-reported benign breast disease history and strata of polygenic risk score, with median polygenic risk score category among women without benign breast disease as the referent. We assessed interactions and mediation of benign breast disease and polygenic risk score with breast cancer risk. Results Benign breast disease history was associated with increased breast cancer risk (odds ratio [OR] = 1.48, 95% confidence interval [CI] = 1.37 to 1.60; P < .001). Polygenic risk score increased breast cancer risk, irrespective of benign breast disease history (Pinteraction = .48), with minimal evidence of mediation of either factor by the other. Women with benign breast disease and polygenic risk score in the highest tertile had more than twofold increased odds of breast cancer (OR = 2.73, 95% CI = 2.41 to 3.09), and those with benign breast disease and polygenic risk score in the lowest tertile experienced reduced breast cancer risk (OR = 0.79, 95% CI = 0.70 to 0.91) compared with the referent group. Women with benign breast disease and polygenic risk score in the highest decile had a 3.7-fold increase (95% CI = 3.00 to 4.61) compared with those with median polygenic risk score without benign breast disease. Conclusion Breast cancer risks are elevated among women with benign breast disease and increase progressively with polygenic risk score, suggesting that optimal combinations of these factors may improve risk stratification.
Development of a Breast Cancer Risk Prediction Model Integrating Monogenic, Polygenic, and Epidemiologic Risk
Kalia, Sarah S. , Boddicker, Nicholas , Yadav, Siddhartha , Huang, Hongyan , Na, Jie , Ambrosone, Christine B. , Yao, Song , Haiman, Christopher A. , Chen, Fei , John, Esther M. , Kurian, Allison W. , Guo, Boya , Lindström, Sara , Auer, Paul L. , Taylor, Jack A. , Hodge, James M. , Lori, Adriana , Bodelón, Clara , Vachon, Celine M. , Goldgar, David E. , Nathanson, Katherine L. , Weitzel, Jeffrey N. , Boddicker, Nicholas J , Hu, Chunling , Ambrosone, Christine B , Yao, Song , Haiman, Christopher A , Chen, Fei , John, Esther M , Kurian, Allison W , Guo, Boya , Lindstrom, Sara , Auer, Paul , Lacey, James V. , Neuhausen, Susan L. , Martı́nez, Marı́a Elena , Sandler, Dale P , O'Brien, Katie M , Taylor, Jack A , Teras, Lauren R , Hodge, James M , Lori, Adriana , Bodelon, Clara , Trentham-Dietz, Amy , Burnside, Elizabeth S , Vachon, Celine M. , Winham, Stacey J , Goldgar, David E , Domchek, Susan M , Nathanson, Katherine L , Weitzel, Jeffrey N , Couch, Fergus J. , Kraft, Peter , Yadav, Siddhartha , Na, Jie , Hu, Chunling , Sandler, Dale P. , O’Brien, Katie M. , Teras, Lauren R. , Trentham‐Dietz, Amy , Burnside, Elizabeth S. , Winham, Stacey J. , Domchek, Susan M. , Couch, Fergus J. , Kraft, Peter

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | September 11, 2024 | Volume: 33 | Issue: 11 | Pages: 1490-1499

10.1158/1055-9965.epi-24-0594 | PMID 39259185 Get It

Abstract Background: Breast cancer has been associated with monogenic, polygenic, and epidemiologic (clinical, reproductive, and lifestyle) risk factors, but studies evaluating the combined effects of these factors have been limited. Methods: We extended previous work in breast cancer risk modeling, incorporating pathogenic variants (PV) in six breast cancer predisposition genes and a 105-SNP polygenic risk score (PRS), to include an epidemiologic risk score (ERS) in a sample of non-Hispanic White women drawn from prospective cohorts and population-based case–control studies, with 23,518 cases and 22,832 controls, from the Cancer Risk Estimates Related to Susceptibility (CARRIERS) Consortium. Results: The model predicts 4.4-fold higher risk of breast cancer for postmenopausal women with no predisposition PV and median PRS, but with the highest versus lowest ERS. Overall, women with CHEK2 PVs had >20% lifetime risk of breast cancer. However, 15.6% of women with CHEK2 PVs and a family history of breast cancer, and 45.1% of women with CHEK2 PVs but without a family history of breast cancer, had low (<20%) predicted lifetime risk and thus were below the threshold for MRI screening. CHEK2 PV carriers at the 10th percentile of the joint distribution of ERS and PRS, without a family history of breast cancer, had a predicted lifetime risk similar to the general population. Conclusions: These results illustrate that an ERS, alone and combined with the PRS, can contribute to clinically relevant risk stratification. Impact: Integrating monogenic, polygenic, and epidemiologic risk factors in breast cancer risk prediction models may inform personalized screening and prevention efforts.